Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab′)2

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 4, 2006, Pages 1228-1237

  Elgqvist, Jörgen ^a   Andersson, Håkan ^a   Bernhardt, Peter ^a   Bäck, Tom ^a   Claesson, Ingela ^a   Hultborn, Ragnar ^a   Jensen, Holger ^b   Johansson, Bengt R ^c   Lindegren, Sture ^a   Olsson, Marita ^c   Palm, Stig ^a   Warnhammar, Elisabet ^a   Jacobsson, Lars ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Astatine; Dosimetry; MX35; Ovarian cancer; Radioimmunotherapy

Indexed keywords

DISEASE CONTROL; DOSIMETRY; DRUG THERAPY; IMMUNOLOGY; MEASUREMENT THEORY; PROBABILITY; RADIOTHERAPY; TUMORS;

OVARIAN CANCER; RADIOIMMUNOTHERAPY; TUMOR-FREE FRACTION (TFF);

BIODIVERSITY;

ASTATINE 211; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MX 35; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CANCER CELL; CELL LINE; CELL NUCLEUS; CONTROLLED STUDY; DOSIMETRY; DRUG ACTIVITY; DRUG EFFICACY; ENERGY; FEMALE; INOCULATION; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; DATA INTERPRETATION, STATISTICAL; DOSE FRACTIONATION; FEMALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 33750320371     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.07.003     Document Type: Article

References (35)

1. McQuarrie S., Mercer J., Syme A., et al. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J Pharm Pharm Sci 7 (2005) 29-34
2. Janssen M.L., Pels W., Massuger L.F., et al. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide. Int J Gynecol Cancer 13 (2003) 607-613
3. Borchardt P.E., Quadri S.M., Freedman R.S., et al. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis. Cancer Biother Radiopharm 15 (2000) 53-64
4. Grana C., Bartolomei M., Handkiewicz D., et al. Radioimmunotherapy in advanced ovarian cancer: Is there a role for pre-targeting with (90)Y-biotin?. Gynecol Oncol 93 (2004) 691-698
5. Meredith R.F., Alvarez R.D., Partridge E.E., et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A Phase I study. Cancer Biother Radiopharm 16 (2001) 305-315
6. Mahe M.A., Fumoleau P., Fabbro M., et al. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 5 Suppl (1999) 3249-3252
7. Epenetos A.A., Hird V., Lambert H., et al. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 10 (2000) 44-46
8. 177Lu-CC49: A phase I/II study. Gyncol Oncol 65 (1997) 94-101
9. 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 8 (2002) 2806-2811
10. Stewart J.S.W., Hird V., Snook D., et al. Intraperitoneal Yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 8 (1990) 1941-1950
11. Seiden M, Benigno BB, The SMART Study Investor Group (Southeastern Gynecological Oncology). A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2004, Abstract No. 5008.
12. Horak E., Hartmann F., Garmestani K., et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med 38 (1997) 1944-1950
13. Borchardt P.E., Yuan R.R., Miederer M., et al. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 63 (2003) 5084-5090
14. 211At-labelled monoclonal antibody MOv18. Anticancer Res 20 (2000) 459-462
15. 211At in nude mice with intraperitoneally growing ovarian cancer xenografts: A long term study. Acta Oncol 39 (2000) 741-745
16. 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian carcinoma. Anticancer Res 21 (2001) 409-412
17. 211At-labeled monoclonal antibody MX35. J Nucl Med 46 (2005) 1907-1915
18. Elgqvist J., Andersson H., Bäck T., et al. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med 47 (2006) 1342-1350
19. 211At-labeled human/mouse chimeric monoclonal antibody: A long-term survival study with histological analysis. Int J Radiat Oncol Biol Phys 45 (1999) 491-499
20. 211At in a murine intraperitoneal tumor model. Gynecol Oncol 57 (1995) 9-15
21. 60Co irradiation in nude mice. J Nucl Med 46 (2005) 464-471
22. Bernhardt P., Ahlman H., and Forssell-Aronsson E. Modelling of metastatic cure after radionuclide therapy: Influence of tumor distribution, cross-irradiation, and variable activity concentration. Med Phys 31 (2004) 2628-2635
23. Lindegren S., Bäck T., and Jensen H.J. Dry-distillation of astatine-211 from irradiated bismuth targets: A time-saving procedure with high recovery yields. Appl Radiat Isotopes 55 (2001) 157-160
24. Welshinger M., Yin B.W.T., and Lloyd K.O. Initial immunochemical characterization of MX35 ovarian cancer antigen. Gynecol Oncol 67 (1997) 188-192
25. Rubin S.C., Kostakoglu L., Divgi C., et al. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gynecol Oncol 51 (1993) 61-66
26. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
27. Lindegren S., Andersson H., Bäck T., et al. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidizing agent in labeling of N-succinimidyl 3-(trimethylstannyl)benzoate. Nucl Med Biol 28 (2001) 33-39
28. Hamilton T.C., Young R.C., McKoy W.M., et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43 (1983) 5379-5389
29. Lindmo T., Boven E., Cuttitta F., et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72 (1984) 77-89
30. Friedman P.L., and Ellisman M.H. Enhanced visualization of peripheral nerve and sensory receptors in the scanning electron microscope using cryofracture and osmium-thiocarbohydrazide-osmium impregnation. J Neurocytol 10 (1981) 111-131
31. Palm S., Humm J.L., Rundqvist R., et al. Microdosimetry of astatine-211 single-cell irradiation: Role of daughter polonium-211 diffusion. Med Phys 31 (2004) 218-225
32. ICRU. Stopping powers and ranges for protons and alpha particles. Publication 49. Bethesda, Maryland: International Commission on Radiation Units and Measurements; 1993.
33. Sgouros G. Plasmapheresis in radioimmunotherapy of micrometastases: A mathematical modeling and dosimetrical analysis. J Nucl Med 33 (1992) 2167-2179
34. 211At-radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of RBE of an alpha emitter in vivo. J Nucl Med 46 (2005) 2061-2067
35. 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines. Anticancer Res 20 (2000) 1005-1012